GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 60 Degrees Pharmaceuticals Inc (NAS:SXTP) » Definitions » Change In Prepaid Assets

SXTP (60 Degrees Pharmaceuticals) Change In Prepaid Assets : $0.89 Mil (TTM As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is 60 Degrees Pharmaceuticals Change In Prepaid Assets?

60 Degrees Pharmaceuticals's Change In Prepaid Assets for the quarter that ended in Sep. 2024 was $-0.25 Mil. It means 60 Degrees Pharmaceuticals's Prepaid Assets declined by $0.25 Mil from Jun. 2024 to Sep. 2024 .

60 Degrees Pharmaceuticals's Change In Prepaid Assets for the fiscal year that ended in Dec. 2023 was $-0.52 Mil. It means 60 Degrees Pharmaceuticals's Prepaid Assets declined by $0.52 Mil from Dec. 2022 to Dec. 2023 .


60 Degrees Pharmaceuticals Change In Prepaid Assets Historical Data

The historical data trend for 60 Degrees Pharmaceuticals's Change In Prepaid Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

60 Degrees Pharmaceuticals Change In Prepaid Assets Chart

60 Degrees Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Change In Prepaid Assets
-0.30 0.14 0.03 -0.52

60 Degrees Pharmaceuticals Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Change In Prepaid Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.48 0.99 0.06 0.09 -0.25

60 Degrees Pharmaceuticals Change In Prepaid Assets Calculation

Change In Prepaid Assets is any increase or decrease between periods of the prepaid assets.

Change In Prepaid Assets for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


60 Degrees Pharmaceuticals Change In Prepaid Assets Related Terms

Thank you for viewing the detailed overview of 60 Degrees Pharmaceuticals's Change In Prepaid Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


60 Degrees Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
Executives
Geoffrey S Dow director, 10 percent owner, officer: CEO and President 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Cheryl Xu director 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Charles W Allen director 1881 N. NASH STREET, UNIT 701, ARLINGTON VA 22209
Kentucky Technology Inc. 10 percent owner 824 BULL LEA RUN, SUITE 2100, LEXINGTON KY 40511
Paul Field director 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Tyrone Miller officer: Chief Financial Officer 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Florida State University Research Foundation Inc. 10 percent owner 200 LEVY AVENUE, BUILDING A, SUITE 351, TALLAHASSEE FL 32310
Bryan Lee Smith officer: Chief Medical Officer 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Stephen Toovey director 1025 CONNECTICUT AVENUE NW, SUITE 100, WASHINGTON DC 20036

60 Degrees Pharmaceuticals Headlines

From GuruFocus